PLETAL Drug Patent Profile

When do Pletal patents expire, and when can generic versions of Pletal launch?

Pletal is a drug marketed by Otsuka and is included in one NDA.

The generic ingredient in PLETAL is cilostazol. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cilostazol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pletal

A generic version of PLETAL was approved as cilostazol by EPIC PHARMA LLC on November 23^rd, 2004.

Summary for PLETAL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PLETAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	PLETAL	cilostazol	TABLET;ORAL	020863-001	Jan 15, 1999		DISCN	Yes	No
Otsuka	PLETAL	cilostazol	TABLET;ORAL	020863-002	Jan 15, 1999		DISCN	Yes	No

International Patents for PLETAL

See the table below for patents covering PLETAL around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	792699
Italy	1119929	DERIVATI DEL TETRAZOLIL ALCOSSI CARBOSTIRILE E PROCEDIMENTO PER LA LORO FABBRICAZIONE
Denmark	158788
Portugal	70136
Denmark	363179
Australia	5039779
U.S.S.R.	1064868	PROCESS FOR PREPARING TETRAZOLYLALKOXYCARBOSTYRILES

PLETAL Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Current Market and Investment Landscape for PLETAL?

PLETAL (cilostazol) is a phosphodiesterase III inhibitor marketed primarily for treating intermittent claudication caused by peripheral arterial disease. Its market presence remains limited, predominantly in Japan, where it holds marketing authorization, with minimal penetration elsewhere. The pharmaceutical's investment potential hinges on regulatory, patent, and market dynamics.

What Are the Patent and Regulatory Statuses of PLETAL?

As of the latest available data, PLETAL's patent protection has expired in several jurisdictions, including the US and Europe. Its exclusivity in Japan persists, where it has been marketed since the 1990s. Regulatory pathways for potential reformulation or new indications could revive interest but remain uncertain.

• Patent expiry: US (2010), Europe (2012), Japan (2020+)
• Regulatory approvals: Approved in Japan, not approved in the US or EU for new indications

The expiration of key patents diminishes exclusivity, opening the market for generics, which could erode revenue streams and impact investor interest.

What Are the Market Fundamentals and Revenue Analytics?

The drug primarily targets peripheral vascular disease, a condition with an aging global population. Japan’s market accounts for the majority of sales, estimated at approximately USD 200 million annually. The US and Europe have negligible sales due to lack of approval.

• Japanese market revenue: USD 200 million (estimated 2022)
• Global market share: Limited, due to regulatory and competitive factors
• Generics impact: Increased competition post-patent expiry could reduce prices and sales

Given the limited geographic footprint and aging demographics in Japan, growth potential is constrained unless a new indication or reformulation garners approval.

What Are the Competitive and Regulatory Challenges?

PLETAL faces competition from alternative treatments for peripheral arterial disease, including walking therapy, other drugs (e.g., pentoxifylline), and endovascular procedures. Regulatory hurdles include the absence of approval outside Japan and the lack of a clear pipeline for new indications.

• Competitive landscape: Fragmented, with no dominant global alternative
• Regulatory hurdles: Need for new clinical evidence for expanded use; high costs and long timelines

The absence of current approval outside Japan limits global revenue streams, reducing the attractiveness for broad-based investors.

What Are the R&D and Pipeline Considerations?

No recent or active clinical trials have been launched for PLETAL's new indications or reformulations. Future R&D investments would target indications with unmet medical needs, such as ischemic stroke or coronary artery disease, contingent on favorable regulatory pathways.

• Clinical pipeline: No active global trials
• Potential indications: Stroke, coronary artery disease (hypothetical)
• Regulatory challenges: Need substantial clinical data, high development costs

Without a strategic R&D push, the drug's future growth prospects diminish significantly.

What Are the Investment Risks and Opportunities?

Risks:

1. Patent expiration leading to generic competition, eroding margins
2. Regulatory barriers reducing potential markets
3. Limited pipeline reducing long-term revenue prospects
4. Competition from new drugs and procedural interventions

Opportunities:

1. Potential for a new formulation or delivery method that extends patent protection
2. Possible expansion into new indications with accelerated pathways
3. Market consolidation in Japan could sustain sales momentum
4. Licensing or partnership deals for development in other regions

The investment scenario relies heavily on strategic regulatory and pipeline developments.

Key Takeaways

• PLETAL's patent estate has diminished, limiting its revenue growth potential outside Japan.
• Its market is constrained by competitive alternatives and regulatory limitations in non-Japanese regions.
• The drug's current revenue relies heavily on Japanese sales, with minimal expansion prospects.
• Future growth depends on pipeline innovation, new indications, or reformulation efforts.
• Risk management should focus on patent expiration, generic entry, and regulatory hurdles.

FAQs

1. Given patent expiration, how viable is PLETAL as an investment?
Its viability diminishes due to generic competition, unless a new formulation or indication is developed and approved.

2. Can PLETAL expand globally?
Without regulatory approval outside Japan, global expansion remains unlikely without significant clinical trial investment.

3. Are there any ongoing clinical trials for PLETAL?
No current active clinical trials are publicly known for new indications or reformulations.

4. What are the primary competitive advantages of PLETAL?
Limited to its established efficacy in Japan and its longstanding market presence.

5. What strategic moves could improve PLETAL's market position?
Developing a new formulation, expanding indications, or partnering for licensing could restore growth potential.

References

[1] Pfizer Inc. (2009). Cilostazol (Pletal) Highlights of Prescribing Information.
[2] GlobalData. (2022). Peripheral Arterial Disease Market Analysis.
[3] Japan Pharmaceuticals and Medical Devices Agency (PMDA). (2023). Drug Approvals.
[4] U.S. Patent and Trademark Office (USPTO). (2022). Patent Expiry Data.